Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights

HERZLIYA, Israel and CALGARY, AB, Feb. 13, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), is pleased to provide the following corporate update: Innocan is uniquely positioned within the pharmaceutical technology industry…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.